Accolade, Inc.

Accolade — Investor Presentation (January 2024)

39 slides from Accolade's investor presentation, January 2024

  1. Slide 1: Accolade Inc. Investor Presentation

    January 2024 NASDAQ: ACCD Accolade Inc. Investor Presentation

  2. Slide 2: Forward-looking statements

    This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b

  3. Slide 3: Building a customer-obsessed, nationwide healthcare delivery company

    Building a customer-obsessed, nationwide healthcare delivery company 3 Accolade ©2024 - Confidential

  4. Slide 4: Investment Highlights

    Investment Highlights Targeting $1B in revenue and 15-20% Adjusted EBITDA in 5 years Consistent 20% revenue growth with increasing profitability Market leader in highly underpenetrated Personalized Healthcare market High revenue visibility and customer diversification Integrated platform enables sca

  5. Slide 5: What stands us apart

    World-class Partner technology platform What stands us apart Broad customer Flywheel profile value 5 Accolade ©2024 - Confidential

  6. Slide 6: High Touch Healthcare Services Powered by Next Gen Technology

    High Touch Healthcare Care Nurse Case Women’s Behavioral Health Health Services Powered by Nurses Advocates Managers Nurses Clinician Next Gen Technology Physicians (typically internal medicine or family practice) Panel of 1000+ Physician Our extraordinary care teams drive engagement, Specialists so

  7. Slide 7: The Physician Gap impact is real

    Delayed and deferred doctor visits the Physician Gap Fragmented communication impact is real between providers (episodes) Unnecessary surgeries and wrong treatments 7 Accolade ©2024 - Confidential

  8. Slide 8: We put doctors at the heart of the solution

    We put doctors at the heart of the solution Physician-led Care Team Internal Physicians & Therapists Elite Specialists Expert Nurses Care Advocates Doctor-to-doctor Support Targeted outreach Single Point of Entry data sharing Benefits Verification of benefits ID card Claims and appeals Utilization m

  9. Slide 9: Accolade fixes the Physician Gap

    80% of visits occur same day Accolade fixes Data sharing with the Physician Gap outside physicians visit summaries and relevant data Overall savings: 4%+ EMO: 25% of surgeries cancelled, 85% care plans improved 9 Accolade ©2024 - Confidential

  10. Slide 10: Trust and human connection, every time

    Trust and human connection, every time Member fingerprint Specific care team matching Integrated point True Health Actions solutions and care pathways 10 Accolade ©2024 - Confidential

  11. Slide 11: Our World-Class Technology

    Member Call Our Fingerprint Scheduling World-Class Technology Skills-Based Routing Automation We use technology and data to seamlessly give members trust and human connection, every time. TrueHealth AI Actions 11 Accolade ©2024 - Confidential

  12. Slide 12: The future state is connected for ease

    The future state is connected for ease Specialists Front door engagement Meds Pre-existing burdens Therapy SDOH Primary Care Benefits Point Solutions Lack of combined data timely Telehealth is used to form care High-risk member True Health Actions Urgent Actionable steps Care are given to member in

  13. Slide 13: True Health Actions Drive Personalized Care Experience

    True Health Actions A Drive Personalized Care Experience B A Concept – Member Health Snapshot B Deployed – Alerts C C Deployed – True Health Action Recommendations 13 Accolade ©2024 - Confidential

  14. Slide 14: True Health Actions Create a Personalized Digital Experience

    True Health Actions Create a Personalized Digital Experience Accolade Driven user need “For you” Support call(s) to action (True Health Actions) Member Driven user need “Ways we can help” Bring User Need resolution paths to front 14 Accolade ©2024 - Confidential

  15. Slide 15: What AI means at Accolade

    Artificial Intelligence A program and capabilities that can sense, reason, act, and adapt Machine Learning What AI means Algorithms whose performance improve as they are exposed to more data over time at Accolade Data Platform Foundational multi-layered data architecture that is the proprietary sour

  16. Slide 16: Our AI capabilities and utilization

    Our AI capabilities and utilization § Interaction Monitoring § Population Health § Clinical Analytics § Auto QA Evaluations § Clinical Foundation Score § Workforce Management Forecasting § Auto Note Summarization § EMO ML Models § NPS and CSAT Sentiment § Conversational AI across IVR § Decision & Wo

  17. Slide 17: Accolade's Advantages for the Healthcare Ecosystem

    Accolade’s Advantages for the Healthcare Ecosystem Front Line Care Teams Data set End to end reporting 17 Accolade ©2024 - Confidential

  18. Slide 18: Trusted Partner Ecosystem

    Trusted Partner Ecosystem High-quality solutions, complementary to Accolade’s own services, in categories that matter to our customers Musculoskeletal Diabetes / Metabolic Pharmacy Centers of Excellence Behavioral Health Health Equity [object File] Gastrointestinal Fertility Healthcare Wellness / In

  19. Slide 19: Driving appropriate use of customers' programs is core to our value proposition

    Driving appropriate use of customers’ programs is core to our value proposition Ecosystem Programs Trusted Partner Ecosystem Existing point solutions Best-in-class solutions where customers enjoy easier purchasing and + implementation, enhanced features, and incremental utilization Benefit Warm site

  20. Slide 20: Business Model Builds Momentum as Adoption Grows

    Engage Partner Identify Business Model Builds Momentum as Adoption Grows Expert Route MD Primary Care 20 Accolade ©2024 - Confidential

  21. Slide 21: Distribution Reach

    Distribution Reach 21 Accolade ©2024 - Confidential

  22. Slide 22: Diversified customer profiles create opportunity and expand TAM

    Diversified customer profiles create opportunity and expand TAM • Diversified across • Size • Industry • Enterprise, government, Broad customer health plan, consumer profile • Direct • Health Plan • Integrated • Consumer Multi-offering • Ecosystem Partners Diversified • Leverage investments platform

  23. Slide 23: Business Model Builds Momentum as Adoption Grows

    Business Model Builds Momentum as Adoption Grows Early and Repeat Expert Physicians Engagement Diagnosis & Treatment Review Member Insights and care recommendation 69% PCPs & Therapists Acute, Chronic & Preventive Ongoing data analysis Care team interaction and influence Registered Member Nurses Car

  24. Slide 24: Improved Outcomes Across Conditions

    Improved Outcomes Across Conditions No True One or more True Improvement Health Action Health Action Musculoskeletal AVOIDABLE ER VISITS 57% members engaged 44% received 1+ Interventions 15% 13% -13% Depression or Anxiety OUTPATIENT BH VISITS (per member per year) 47% members engaged 35% received 1+

  25. Slide 25: Financials

    Financials

  26. Slide 26: Accelerating Accolade's Innovation

    Accelerating Accolade’s Innovation Continuous investment in clinical transformation and operational excellence Created a Proven Launched Intelligent Launched Launched Mental Acquired 2nd.MD - Acquired PlushCare - Introduced High Touch, High Provider Matching Accolade COVID Health Integrated Expert M

  27. Slide 27: Significantly Expanded Addressable Market

    Significantly Expanded Addressable Market $216 billion TAM 900 Customers 800+ $170B 800 Primary Care 700 600+ 600 500 $22B 400 Expert Medical Opinion 300 200 $24B 112 Navigation & Advocacy 100 54 15 20 0 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 (w M&A) 27 Accolade ©2024 - Confidential

  28. Slide 28: Consistent growth and progress toward profitability

    Consistent growth and progress toward profitability Revenue R ~$413M 33% CAG $363M $310M $170M $133M FY20 FY21 FY22 FY23 FY24P Adjusted EBITDA (Loss) & Adjusted OpEx as % of revenue 70% 61% 60% 57% ~50% -16% -14% -10% -25% -2% FY20 FY21 FY22 FY23 FY24P 28 FYE = February

  29. Slide 29: Strong visibility to growth and profitability

    Strong visibility to growth and profitability Targeting $1 billion revenue and 15-20% Adjusted EBITDA in FY29 Revenue AEBITDA $1B+ Horizon 2 Key drivers • Integrated healthcare platform Horizon 1 G R o Advocacy CA o Primary Care and mental health 0% 2 o Expert Medical Opinion ~$500M o Trusted Partne

  30. Slide 30: Customer and revenue diversification

    Customer and revenue diversification FY23 800+ customers FY20 § 200+ Advocacy § 600+ EMO § Launched eVPC in past year § >10% with >1 core offering § No 5% customer in FY24P § Broad industry diversification § 54 customers § 6 customers ~ 75% of revenue 30 Accolade ©2024 - Confidential

  31. Slide 31: Financial Targets and Goals (Non-GAAP)

    Long-Term Goals Adj. Gross Margin 50-55% P&T as 13-17% Financial Targets % of Rev. and Goals Adj. S&M as Operating 15-20% (Non-GAAP) Expenses % of Rev. G&A as 7-9% % of Rev. Adj. EBITDA Margin 15-20% 31 Accolade ©2024 - Confidential

  32. Slide 32: Growth, Scale & Profitability

    Growth, Scale & Profitability Highly diversified revenue mix Expanding margins and operating leverage One Accolade driving operational efficiencies Attractive and improving unit economics Clear vision toward $1B+ revenue and target financial model Accolade ©2023 32

  33. Slide 33: Accolade Personalized Healthcare

    Accolade PERSONALIZED HEALTHCARE

  34. Slide 34: Appendix

    Appendix 34

  35. Slide 35: Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA

    Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and severance costs. We define Adjus

  36. Slide 36: Adjusted EBITDA (Loss) Reconciliation

    Adjusted EBITDA (Loss) Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2020 2021 2022 2023 Net Loss $ (51,365) $ (50,652) $ (123,124) $ (459,650) Adjusted for: Interest expense (income), net 2,925 3,724 2,905 (255) Income tax expense (benefit) 129 4 (5,639) (3,624) Depreciation a

  37. Slide 37: Adjusted Gross Margin Reconciliation

    Adjusted Gross Margin Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2020 2021 2022 2023 Revenue $ 132,507 $ 170,358 $ 310,021 $ 363,142 Less: Cost of revenue, excluding depreciation and (73,685) (93,673) (169,019) (198,905) amortization Gross Profit, excluding depreciation and

  38. Slide 38: Adjusted Operating Expense Reconciliation

    Adjusted Operating Expense Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2020 2021 2022 2023 Revenue $ 132,507 $ 170,358 $ 310,021 $ 363,142 Operating Expenses 107,026 123,462 266,727 627,751 Less: Depreciation and amortization (8,516) (8,212) (42,608) (46,377) Stock-based comp

  39. Slide 39: Accolade Personalized Healthcare

    Accolade PERSONALIZED HEALTHCARE

Accolade — Investor Presentation (January 2024) on 6ix